The company issued preliminary guidance for 2017 of $260 million to $275 million in revenues and adjusted EPS of between $.17 and $.22.
The company lowered its financial guidance for fiscal 2016, citing delays in recognizing fourth quarter revenue from its pharma services business.
The revenue growth was driven by clinical genetic testing volume, which benefitted from the inclusion of the 2015 acquisition of Clarient.
The investment bank said NeoGenomics and its clients are likely to benefit from a product portfolio expanded by the acquisition of Clarient.
The company's Q2 net loss attributable to common stockholders widened to $5.2 million from essentially break even a year ago.
The company's net loss in the quarter grew nearly eightfold, primarily due to the impact of preferred dividends and stock tied to the acquisition of Clarient.
Excluding acquisitions PathLogic and Clarient, base test volume grew 25 percent in the quarter amid increases in all product lines across all regions.
The cancer genetics testing provider acquired its new business unit from GE Healthcare.
Following Covance's acquisition by LabCorp, NeoGenomics will no longer be an exclusive testing services partner but will receive a $2 million payment.
By buying Clarient, NeoGenomics hopes to move closer to its goal of becoming America's top cancer genetic testing lab.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.